Skip to content

Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease

Residual Platelet Activity Despite Aspirin Utilization in Patients With Non ST Elevation Acute Coronary Syndromes: Comparison Between the Acute and Chronic Phases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01820429
Enrollment
70
Registered
2013-03-28
Start date
2009-12-31
Completion date
2012-04-30
Last updated
2013-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease, Non ST-elevation Acute Coronary Syndromes

Keywords

Platelet aggregation, Aspirin

Brief summary

The purpose of this study is to compare the response to aspirin in the acute phase with the late phase of an acute coronary syndrome.

Detailed description

The purpose of this study is to compare, in the same population, the response to aspirin in the initial phase (first 48 hours) with the late phase (after 3 months of discharge)of a non ST elevation acute coronary syndrome (angina or acute myocardial infarction).

Interventions

None listed

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Confirmed diagnosis of acute coronary syndrome without ST segment elevation, in the first 48 hours after the onset of the clinical symptoms * Regular use of aspirin for at least seven days.

Exclusion criteria

* Previous use, in the last 7 days, of another antiplatelet agent than aspirin * Use of antivitamin K in the last 3 weeks * Hemoglobin \< 10g/dL and / or hematocrit \< 30% or \> 50%, platelets count \< 100.000/mm3 or \> 500.000/mm3, creatinine clearance \< 30 mL / minute * Killip class III or IV * Need for vasopressor or inotropic parenteral medication at inclusion in the study * Percutaneous coronary intervention within 30 days or CABG in the last 90 days prior to study entry * Current malignancy * Hematologic diseases * Refusal to sign the inform consent form * Unable to attend the second visit (follow-up) for any reason except for death

Design outcomes

Primary

MeasureTime frame
Compare platelet aggregation between the first 48 hours and 3 months after discharge.3 months

Secondary

MeasureTime frameDescription
Relation between platelet aggregability and the composite endpoint of death, myocardial infarction, unstable angina and need for revascularization or hospitalization at 3 months after discharge.3 months
Relation between the atherosclerotic burden by coronary angiography with the platelet aggregation in the first 48 hours.48 hours
Relation between C reactive protein and interleukin -6 with levels of platelet aggregation.first 48 hours and 3 months
Relation between platelet aggregation and the presence or absence of selected polymorphisms.first 48 hours and 3 months
Platelet aggregation in respect to age, gender, glucose at hospital arrival, glycated hemoglobin, statin, PPI, current smokers, ACE inhibitors, type of ACS presentation.first 48 hours and 3 monthsCut point for age 65 y, for glycemia 125 mg/dL, for glycated hemoglobin 6%

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026